Research Analysts Issue Forecasts for DexCom FY2026 Earnings

Key Points

• Analysts at Leerink Partners have revised DexCom's FY2026 earnings per share estimate down to $2.69, from a previous estimate of $2.74, while the consensus for FY2025 is $2.03 EPS.
• Multiple brokerages have raised their price targets for DexCom, with Mizuho targeting $100 and Canaccord Genuity setting a target of $106, indicating strong investor interest.
• DexCom's stock recently opened at $66.21 and has demonstrated a significant range over the past year, with a 12-month high of $93.25 and a low of $57.52.

DexCom, Inc. (NASDAQ:DXCM - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2026 earnings per share (EPS) estimates for shares of DexCom in a research report issued to clients and investors on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings of $2.69 per share for the year, down from their previous forecast of $2.74. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. Leerink Partnrs also issued estimates for DexCom's FY2027 earnings at $3.23 EPS, FY2028 earnings at $3.92 EPS and FY2029 earnings at $4.65 EPS.

A number of other brokerages have also recently issued reports on DXCM. Morgan Stanley boosted their target price on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Mizuho boosted their target price on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Canaccord Genuity Group reissued a "buy" rating and set a $106.00 price target on shares of DexCom in a research report on Monday, September 29th. Raymond James Financial boosted their price target on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. Finally, Robert W. Baird reduced their price target on DexCom from $112.00 to $90.00 and set an "outperform" rating on the stock in a research report on Friday, September 26th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $97.42.

DexCom Stock Up 1.5%

DXCM opened at $66.21 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The stock has a market capitalization of $25.96 billion, a price-to-earnings ratio of 45.98, a price-to-earnings-growth ratio of 1.37 and a beta of 1.47. The business has a 50-day moving average of $74.01 and a two-hundred day moving average of $77.62. DexCom has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm's revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of DexCom by 1.8% in the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company's stock valued at $4,218,063,000 after buying an additional 866,506 shares during the period. Jennison Associates LLC lifted its holdings in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company's stock valued at $1,005,367,000 after buying an additional 994,300 shares during the period. Geode Capital Management LLC lifted its holdings in shares of DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company's stock valued at $936,100,000 after purchasing an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of DexCom during the first quarter valued at $554,893,000. Institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This represents a 0.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares of the company's stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.